200 related articles for article (PubMed ID: 22331265)
1. The Aurora A and B kinases are up-regulated in bone marrow-derived chronic lymphocytic leukemia cells and represent potential therapeutic targets.
de Paula Careta F; Gobessi S; Panepucci RA; Bojnik E; Morato de Oliveira F; Mazza Matos D; Falcão RP; Laurenti L; Zago MA; Efremov DG
Haematologica; 2012 Aug; 97(8):1246-54. PubMed ID: 22331265
[TBL] [Abstract][Full Text] [Related]
2. Aurora kinase inhibitory VX-680 increases Bax/Bcl-2 ratio and induces apoptosis in Aurora-A-high acute myeloid leukemia.
Huang XF; Luo SK; Xu J; Li J; Xu DR; Wang LH; Yan M; Wang XR; Wan XB; Zheng FM; Zeng YX; Liu Q
Blood; 2008 Mar; 111(5):2854-65. PubMed ID: 18160664
[TBL] [Abstract][Full Text] [Related]
3. Aurora-A kinase nuclear expression in chronic lymphocytic leukemia.
Inamdar KV; O'Brien S; Sen S; Keating M; Nguyen MH; Wang X; Fernandez M; Thomazy V; Medeiros LJ; Bueso-Ramos CE
Mod Pathol; 2008 Dec; 21(12):1428-35. PubMed ID: 18931650
[TBL] [Abstract][Full Text] [Related]
4. Aurora kinases in childhood acute leukemia: the promise of aurora B as therapeutic target.
Hartsink-Segers SA; Zwaan CM; Exalto C; Luijendijk MW; Calvert VS; Petricoin EF; Evans WE; Reinhardt D; de Haas V; Hedtjärn M; Hansen BR; Koch T; Caron HN; Pieters R; Den Boer ML
Leukemia; 2013 Mar; 27(3):560-8. PubMed ID: 22940834
[TBL] [Abstract][Full Text] [Related]
5. Differentially expressed epigenome modifiers, including aurora kinases A and B, in immune cells in rheumatoid arthritis in humans and mouse models.
Glant TT; Besenyei T; Kádár A; Kurkó J; Tryniszewska B; Gál J; Soós G; Szekanecz Z; Hoffmann G; Block JA; Katz RS; Mikecz K; Rauch TA
Arthritis Rheum; 2013 Jul; 65(7):1725-35. PubMed ID: 23653330
[TBL] [Abstract][Full Text] [Related]
6. AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo.
Yang J; Ikezoe T; Nishioka C; Tasaka T; Taniguchi A; Kuwayama Y; Komatsu N; Bandobashi K; Togitani K; Koeffler HP; Taguchi H; Yokoyama A
Blood; 2007 Sep; 110(6):2034-40. PubMed ID: 17495131
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of mitotic kinase Aurora suppresses Akt-1 activation and induces apoptotic cell death in all-trans retinoid acid-resistant acute promyelocytic leukemia cells.
Xu DR; Huang S; Long ZJ; Chen JJ; Zou ZZ; Li J; Lin DJ; Liu Q
J Transl Med; 2011 May; 9():74. PubMed ID: 21600017
[TBL] [Abstract][Full Text] [Related]
8. Vincristine potentiates the anti-proliferative effect of an aurora kinase inhibitor, VE-465, in myeloid leukemia cells.
Yoshida K; Nagai T; Ohmine K; Uesawa M; Sripayap P; Ishida Y; Ozawa K
Biochem Pharmacol; 2011 Dec; 82(12):1884-90. PubMed ID: 21971583
[TBL] [Abstract][Full Text] [Related]
9. Ras-driven transcriptome analysis identifies aurora kinase A as a potential malignant peripheral nerve sheath tumor therapeutic target.
Patel AV; Eaves D; Jessen WJ; Rizvi TA; Ecsedy JA; Qian MG; Aronow BJ; Perentesis JP; Serra E; Cripe TP; Miller SJ; Ratner N
Clin Cancer Res; 2012 Sep; 18(18):5020-30. PubMed ID: 22811580
[TBL] [Abstract][Full Text] [Related]
10. Response of experimental malignant melanoma models to the pan-Aurora kinase inhibitor VE-465.
Pirker C; Lötsch D; Spiegl-Kreinecker S; Jantscher F; Sutterlüty H; Micksche M; Grusch M; Berger W
Exp Dermatol; 2010 Dec; 19(12):1040-7. PubMed ID: 21087322
[TBL] [Abstract][Full Text] [Related]
11. Differential expression of survivin in bone marrow cells from patients with acute lymphocytic leukemia and chronic lymphocytic leukemia.
Nakagawa Y; Yamaguchi S; Hasegawa M; Nemoto T; Inoue M; Suzuki K; Hirokawa K; Kitagawa M
Leuk Res; 2004 May; 28(5):487-94. PubMed ID: 15068902
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia.
Spartà AM; Bressanin D; Chiarini F; Lonetti A; Cappellini A; Evangelisti C; Evangelisti C; Melchionda F; Pession A; Bertaina A; Locatelli F; McCubrey JA; Martelli AM
Cell Cycle; 2014; 13(14):2237-47. PubMed ID: 24874015
[TBL] [Abstract][Full Text] [Related]
13. Overcoming CML acquired resistance by specific inhibition of Aurora A kinase in the KCL-22 cell model.
Yuan H; Wang Z; Zhang H; Roth M; Bhatia R; Chen WY
Carcinogenesis; 2012 Feb; 33(2):285-93. PubMed ID: 22116466
[TBL] [Abstract][Full Text] [Related]
14. The aurora kinase inhibitor CCT137690 downregulates MYCN and sensitizes MYCN-amplified neuroblastoma in vivo.
Faisal A; Vaughan L; Bavetsias V; Sun C; Atrash B; Avery S; Jamin Y; Robinson SP; Workman P; Blagg J; Raynaud FI; Eccles SA; Chesler L; Linardopoulos S
Mol Cancer Ther; 2011 Nov; 10(11):2115-23. PubMed ID: 21885865
[TBL] [Abstract][Full Text] [Related]
15. Growth suppression and mitotic defect induced by JNJ-7706621, an inhibitor of cyclin-dependent kinases and aurora kinases.
Matsuhashi A; Ohno T; Kimura M; Hara A; Saio M; Nagano A; Kawai G; Saitou M; Takigami I; Yamada K; Okano Y; Shimizu K
Curr Cancer Drug Targets; 2012 Jul; 12(6):625-39. PubMed ID: 22463590
[TBL] [Abstract][Full Text] [Related]
16. Biological characterization of TAK-901, an investigational, novel, multitargeted Aurora B kinase inhibitor.
Farrell P; Shi L; Matuszkiewicz J; Balakrishna D; Hoshino T; Zhang L; Elliott S; Fabrey R; Lee B; Halkowycz P; Sang B; Ishino S; Nomura T; Teratani M; Ohta Y; Grimshaw C; Paraselli B; Satou T; de Jong R
Mol Cancer Ther; 2013 Apr; 12(4):460-70. PubMed ID: 23358665
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of action of a dual Cdc7/Cdk9 kinase inhibitor against quiescent and proliferating CLL cells.
Natoni A; Murillo LS; Kliszczak AE; Catherwood MA; Montagnoli A; Samali A; O'Dwyer M; Santocanale C
Mol Cancer Ther; 2011 Sep; 10(9):1624-34. PubMed ID: 21768328
[TBL] [Abstract][Full Text] [Related]
18. Co-treatment with vorinostat synergistically enhances activity of Aurora kinase inhibitor against human breast cancer cells.
Fiskus W; Hembruff SL; Rao R; Sharma P; Balusu R; Venkannagari S; Smith JE; Peth K; Peiper SC; Bhalla KN
Breast Cancer Res Treat; 2012 Sep; 135(2):433-44. PubMed ID: 22825030
[TBL] [Abstract][Full Text] [Related]
19. AEG-1 overexpression is essential for maintenance of malignant state in human AML cells via up-regulation of Akt1 mediated by AURKA activation.
Long M; Hao M; Dong K; Shen J; Wang X; Lin F; Liu L; Wei J; Liang Y; Yang J; Gu F; Zhang H
Cell Signal; 2013 Jun; 25(6):1438-46. PubMed ID: 23499911
[TBL] [Abstract][Full Text] [Related]
20. The effect of Aurora kinases on cell proliferation, cell cycle regulation and metastasis in renal cell carcinoma.
Li Y; Zhou W; Wei L; Jin J; Tang K; Li C; Teh BT; Chen X
Int J Oncol; 2012 Dec; 41(6):2139-49. PubMed ID: 23007526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
